Skip to content

Home-Based EASE-NOVA Brain Stimulation to Improve Arm and Hand Function After Ischemic Stroke

Home Based tDCS (EASE-NOVA) for Upper Limb Recovery in Ischemic Stroke: A Randomized Controlled Trial - EASE-NOVA

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2026/06/113184
Enrollment
80
Registered
2026-06-30
Start date
Unknown
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: I693- Sequelae of cerebral infarction

Interventions

Intervention1: Active tDCS: Active tDCS (20 minutes) combined with motor training and standard care for 4 weeks, with a total session duration of 1 hour. Control Intervention1: Sham tDCS: Sham tDCS (2

Sponsors

Indian Council of Medical Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Adults aged more than 18 years to 70 years Diagnosed anterior circulation ischemic stroke in the past 3 to 6 months Persistent upper-limb motor impairment (e.g., FMA-UE less than 48) Ability to sit upright and engage in motor tasks Capable of understanding instructions (English/Hindi) Residing at home with a caregiver available for assistance (if needed) fMRI/EEG compatible and able to undergo pre/post scans Willing to provide written informed consent

Exclusion criteria

Exclusion criteria: History of seizures or epilepsy, or current anti-epileptic medication usage Presence of major neurological/psychiatric conditions other than stroke Metallic implants in the head (excluding dental fillings) Presence of pacemaker/other implanted neurostimulators Severe cognitive impairment affecting consent or task participation Pregnant or lactating women Uncontrolled hypertension or cardiac instability Skin lesions or dermatological conditions at electrode sites Contraindications to MRI (claustrophobia, implants, etc.)

Design outcomes

Primary

MeasureTime frame
Fugl Meyer Assessment- Upper Limb at baseline and week 5Timepoint: At baseline and week 5

Secondary

MeasureTime frame
Fugl Meyer Assessment- Upper Limb at week 17Timepoint: At week 17;Modified Barthel Index at baseline , week 5 & week 17Timepoint: at baseline , week 5 & week 17;fMRI at baseline , week 5 & week 17Timepoint: at baseline , week 5 & week 17;Feasibility Adherence rate: Proportion of participants completing more than equal to 80% of prescribed home-based tDCS sessionsTimepoint: ;Safety Outcome: Adverse event monitoring: Incidence and severity of stimulation- related eventsTimepoint:

Countries

India

Contacts

Public ContactDr Ayush Agarwal

All India Institute of Medical Sciences

dr.agarwal.ayush@gmail.com8193900444

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Aug 10, 2026